Modeling and Simulation - PK/PD Archives | 第 11 页，共 37 页 | Certara

On-Demand Webinar

如何在 Phoenix 中执行 C 级 IVIVC

C 级 IVIVC 研究分步指导。

Danielle Pillsbury2017 年 12 月 13 日

Publication

Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

Danielle Pillsbury2017 年 11 月 1 日

Publication

A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies

Danielle Pillsbury2017 年 10 月 30 日

Publication

Influence of Molecular Size on the Clearance of Antibody Fragments

Danielle Pillsbury2017 年 10 月 1 日

White Paper

药物资产评估：提高交易的 "成功概率”

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

Danielle Pillsbury2017 年 8 月 24 日

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

Danielle Pillsbury2017 年 8 月 1 日

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

Danielle Pillsbury2017 年 7 月 15 日

Publication

Interdisciplinary Pharmacometrics Linking Oseltamivir Pharmacology, Influenza Epidemiology and Health Economics to Inform Antiviral Use in Pandemics

Danielle Pillsbury2017 年 7 月 1 日

Publication

Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response

Danielle Pillsbury2017 年 6 月 1 日

On-Demand Webinar

Obeticholic Acid—From PK Model to Drug Label

Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to…

Danielle Pillsbury2017 年 6 月 1 日

© 2025 Certara. 保留所有权力。 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software